Indinol Forto, capsules 60 pcs.

A selective modulator of estrogen receptors.

Indinol Forto is a universal corrector of pathological hyperplastic processes in the breast tissues. The therapeutic effect of Indinol Forto is based on its anti-estrogenic and antiproliferative action.

The main property of the drug Indinol Forto is its ability to induce selective death of the mammary gland cells with abnormally high proliferative activity.

The indolcarbinol in Indinol Forto modulates the cytochrome system so that the resulting cytochrome P450 isoform, CYP1A1, hydroxylates estrogens at the 2nd position to form 2-hydroxyestrone (2-HONE1).

The resulting metabolite is an estrogen receptor antagonist and blocks its activation by estrogens themselves as well as their dangerous metabolites, particularly 16-α-hydroxyestrone (16α-ONE1), whose proportion among metabolites is reduced.

In this way, the induction of estrogen-dependent genes is suppressed and the cell stops receiving excessive estrogen-dependent stimulation. The drug also blocks other signaling mechanisms (cytokines) that stimulate abnormal cell growth in breast tissues by inhibiting signaling cascades from the corresponding receptors.

Course use of the drug promotes reduction of intensity and disappearance of pain syndrome in the breast at cyclic mastalgia (mastodynia).

The use of the drug Indinol Forto does not lead to an increase in body weight. Indinol Forto is practically non-toxic (LD50>5 g/kg).

Indications

Cyclic mastalgia, including against the background of benign mammary hyperplasia.

Pharmacological effect

Selective estrogen receptor modulator.

Indinol Forto is a universal corrector of pathological hyperplastic processes in breast tissue. The therapeutic effect of the drug Indinol Forto is based on its antiestrogenic and antiproliferative effect.

The main property of the drug Indinol Forto is its ability to cause selective death of mammary gland cells with abnormally high proliferative activity.

Indolecarbinol, which is part of the drug Indinol Forto, modulates the cytochrome system in such a way that the resulting isoform of cytochrome P450 – CYP1A1 hydroxylates estrogens in the 2nd position, forming 2-hydroxyestrone (2-ONE1).

The resulting metabolite is an antagonist of the estrogen receptor and blocks its activation by estrogens themselves, as well as their dangerous metabolites, in particular 16-α-hydroxyestrone (16α-ONE1), the share of which among the metabolites decreases.

This suppresses the induction of estrogen-dependent genes, and the cell stops receiving excessive estrogen-dependent stimulation. The drug also blocks other signaling mechanisms (cytokines) that stimulate pathological cell growth in breast tissue by suppressing signaling cascades from the corresponding receptors.

A course of use of the drug helps to reduce the intensity and disappearance of pain in the mammary gland during cyclic mastalgia (mastodynia).

The use of the drug Indinol Forto does not lead to weight gain. Indinol Forto is a practically non-toxic drug (LD50>5 g/kg).

Special instructions

Impact on the ability to drive vehicles and other mechanisms that require increased concentration

Based on the pharmacodynamics and the profile of undesirable effects, it is unlikely that Indinol® Forto affects the ability to drive vehicles and operate machinery.

Active ingredient

Indolecarbinol

Composition

1 capsule:

indolecarbinol 0.2 g

Excipients:

lactose monohydrate (milk sugar) – 0.14 g,

modified corn starch – 0.095 g,

microcrystalline cellulose – 0.064 g,

magnesium stearate – 0.001 g.

Pregnancy

The use of Indinol® Forto is contraindicated during pregnancy and breastfeeding.

Contraindications

The drug should not be used if any of the following conditions are present:

hypersensitivity to the components of the drug;
hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption;
period of pregnancy and breastfeeding;
children under 18 years of age.

Side Effects

From the reproductive system: menstrual cycle disorders in the form of lengthening or shortening.

From the digestive system: epigastric pain.

Laboratory indicators: increased concentrations of thyroid-stimulating and follicle-stimulating hormones, prolactin and estradiol, decreased concentrations of creatinine, eosinophilia.

Other: weight loss. If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Indolecarbinol affects the activity of cytochrome P450 isoenzymes, so caution should be exercised when combined with drugs whose metabolism involves cytochrome P450 isoenzymes (indirect anticoagulants, glucocorticosteroids, oral hypoglycemic agents, antiarrhythmics, antiepileptics, digitalis preparations, sex hormone preparations), as their dose may require adjustment.

Overdose

Symptoms: Possible symptoms of overdose include nausea, vomiting, and diarrhea.

Treatment: specific antidote is unknown.

If an overdose of Indinol® Forto is suspected, symptomatic therapy is recommended.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25°C.

Shelf life

3 years.

Manufacturer

MiraxBioPharma, Russia